美国27-45岁男男性行为者接种HPV疫苗可能具有成本节约性
本研究利用年龄分室的易感-感染-易感模型,评估美国27-45岁男男性行为者(GBMSM)接种人乳头瘤病毒(HPV)疫苗的成本效果。结果显示,将GBMSM疫苗接种年龄上限提高至45岁可节省成本,即接种成本被HPV疾病直接医疗费用的减少所抵消。在多数敏感性分析中,接种至至少40岁均具有成本节约性。
要点
- 将GBMSM的HPV疫苗接种年龄上限提高至45岁具有成本节约性。
- 接种至至少40岁在多数敏感性分析中均节省成本。
- 该结果为27-45岁GBMSM的HPV疫苗接种共同临床决策提供参考。
核心结论
- 对GBMSM接种HPV疫苗至45岁可能是节省公共卫生资源的使用方式。
研究设计与样本
- 采用年龄分室的易感-感染-易感(SIS)模型,模拟美国GBMSM的HPV传播和疾病。
- 评估将GBMSM疫苗接种年龄上限提高至30、35、40或45岁时的效果。
主要发现
- 将GBMSM疫苗接种年龄上限提高至45岁可节省成本,即接种成本被HPV疾病直接医疗费用的减少所抵消。
- 接种至至少40岁在多数敏感性分析中均具有成本节约性。
关键数值与推荐
- 免疫实践咨询委员会(ACIP)推荐11或12岁常规接种HPV疫苗(可从9岁开始),所有26岁及以下人员可补种。
- ACIP推荐27至45岁人群接种HPV疫苗时采用共同临床决策。
- 模型显示对该年龄组广泛接种不具有成本效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Advisory Committee on Immunization Practices (ACIP) recommends routine human papillomavirus (HPV) vaccination at age 11 or 12 years (vaccination can be given starting at age 9 years), with catch-up vaccination for all persons through age 26 years. ACIP recommends shared clinical decision-making for HPV vaccination of persons aged 27 through 45 years, although modeling indicated that broadly vaccinating persons in this age group would not be cost-effective. To help inform clinical decision-making, the objective of this study was to estimate the cost-effectiveness of HPV vaccination among gay, bisexual, and other men who have sex with men (GBMSM) aged 27 through 45 years in the United States. METHOD: We used an age-specific, compartmental, susceptible-infectious-susceptible (SIS) model of HPV transmission and disease among GBMSM to estimate changes in HPV, anogenital wart, and HPV-attributable cancer incidence when the upper age for vaccination among GBMSM was raised to age 30, 35, 40, or 45 years. We then estimated changes in quality adjusted life years (QALYs), costs (vaccination costs and direct medical costs of HPV disease), and the incremental cost-effectiveness ratio under each of these scenarios. RESULTS: Our estimates showed that HPV vaccination of GBMSM was cost-saving through age 45 years, i.e., the costs of vaccination are more than offset by decreases in the direct medical costs of HPV disease. Vaccination of GBMSM through at least age 40 years was cost-saving across most sensitivity analyses. CONCLUSIONS: Vaccination of GBMSM through age 45 years is likely a cost-saving use of public health resources.
引用
- Clay PA, Markowitz LE, Gopalani SV, et al. HPV vaccination among gay, bisexual, and other men who have sex with men aged 27-45 years in the United States is potentially Cost-saving. Vaccine. 2025. PMID: 41056755. doi:10.1016/j.vaccine.2025.127798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。